⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4999739 | 0.62 | — | — | |
| SCHEMBL10760430 | 0.60 | — | — | |
| SCHEMBL8438270 | 0.59 | — | — | |
| SCHEMBL4493809 | 0.59 | — | — | |
| SCHEMBL2407922 | 0.59 | — | — | |
| SCHEMBL1325616 | 0.57 | — | — | |
| SCHEMBL18807835 | 0.57 | — | — | |
| SCHEMBL806334 | 0.56 | — | — | |
| SCHEMBL9786274 | 0.56 | — | — | |
| SCHEMBL6850261 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3797100-A1 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF | Mor Research Applications Ltd. (IL) | 2021-03-31 | — | — | EP | claimed |
| US-20200216419-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2020-07-09 | — | — | US | claimed |
| EP-3052099-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2019-08-21 | — | — | EP | claimed |
| US-20180273511-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2018-09-27 | — | — | US | claimed |
| WO-2017053537-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. (US) | 2017-03-30 | — | — | WO | claimed |
| US-20160235727-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-08-18 | — | — | US | claimed |
| EP-3052099-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2016-08-10 | — | — | EP | claimed |
| WO-2015050798-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | WO | claimed |
| WO-2010141360-A1 | BIARYL BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-12-09 | — | — | WO | claimed |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | claimed |
| EP-0344634-B1 | Bicyclic carboxamides, process for their preparation and medicaments containing them | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-30 | — | — | EP | claimed |
| WO-2024151346-A1 | HETEROARYL FLUOROALKENES AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151759-A1 | HETEROCYCLIC COMPOUNDS AS PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240217989-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-2106260-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | Verva Pharmaceuticals Ltd (AU) | 2009-10-07 | — | — | EP | disclosed |
| WO-2008089521-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | VERVA PHARMACEUTICALS LTD (AU) | 2008-07-31 | — | — | WO | disclosed |
| EP-1908753-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-09 | — | — | EP | disclosed |
| US-5019587-A | Anticoagulants | BOEHRINGER MANNHEIM GMBH (DE) | 1991-05-28 | — | — | US | disclosed |